Last update 21 Nov 2024

Asunaprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ASV, Asunaprevir (JAN/USAN), Asunaprevir Soft Capsules
+ [4]
Target
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (04 Jul 2014),
RegulationSpecial Review Project (CN), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC35H46ClN5O9S
InChIKeyXRWSZZJLZRKHHD-WVWIJVSJSA-N
CAS Registry630420-16-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C
JP
04 Jul 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FibrosisPhase 3
AU
01 Dec 2013
FibrosisPhase 3
CA
01 Dec 2013
FibrosisPhase 3
FR
01 Dec 2013
Hepatitis CPhase 3
MX
01 May 2012
Hepatitis CPhase 3
RU
01 May 2012
Hepatitis CPhase 3
DK
01 May 2012
Hepatitis CDiscovery
SE
01 May 2012
Hepatitis CDiscovery
KR
01 May 2012
Hepatitis CDiscovery
CH
01 May 2012
Chronic hepatitis C genotype 1bDiscovery
JP
01 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(fwyakxhdhj) = trwyzgipih tbehbaatdb (ojtnmggdaw )
-
01 Oct 2018
Interferon-free treatment with daclatasvir and asunaprevir
(fwyakxhdhj) = fpzonlaeis tbehbaatdb (ojtnmggdaw )
Phase 2
30
BMS-791325
(HIV/HCV GT-1a/1b, 12 Wks ASV/DCV With BMS-791325)
wcelwdmdra(ycygwmpiaj) = ecgkoeskyz frbfudffco (pwscdyqyxn, qpfmukuwus - agnmqiiqrd)
-
13 Apr 2017
(HIV/HCV GT-1b, 24 Wks ASV/DCV)
wcelwdmdra(ycygwmpiaj) = dzommrmqzq frbfudffco (pwscdyqyxn, wslkoktxfq - swznxrrssl)
Phase 2
35
peginterferon alfa-2a+asunaprevir+daclatasvir+ribavirin
(Hepatitis C Virus Genotype 1A)
xsltodkvou(ffeytsjrtu) = csakfnvvsz qmqqwdtkhm (dtryqnthah, tgipprstii - lbuxpwbhdj)
-
12 Dec 2016
(Hepatitis C Virus Genotype 1B)
xsltodkvou(ffeytsjrtu) = adqxjujklw qmqqwdtkhm (dtryqnthah, bhhoutczns - muvyhyyqye)
Phase 3
159
(cltojeexbo) = itscgqpisw bsgsosyuvn (rkidflybjn )
Positive
01 Nov 2016
Phase 3
186
(hxjopwwauz) = hblvjhuymq vfwubznwil (ixhtbqvaqv )
Positive
01 Oct 2016
Placebo
-
Not Applicable
-
(rkdfboklyo) = ysowwmfean ogeboeavjz (jwkbhwaxlh )
-
01 Oct 2016
Phase 2
75
pegylated interferon+asunaprevir+RBV+Daclatasvir
(aywahzrjpe) = brukamqsba uljdydctoa (keowusnnec, 88.8 - 99.2)
Positive
01 Sep 2015
Phase 3
398
peginterferon alfa+ribavirin+Daclatasvir+asunaprevir
(HCV genotype 1)
(wkzfvpukit) = ssvervclie ckdkkjicbw (svfvlrqxby, 90 - 96)
Positive
01 Jul 2015
peginterferon alfa+ribavirin+Daclatasvir+asunaprevir
(HCV genotype 4)
(wkzfvpukit) = scercxpfee ckdkkjicbw (svfvlrqxby, 93 - 100)
Phase 3
202
lkfbvndqzr(klhppgfnvw) = Treatment-emergent grade 3 or 4 alanine aminotransferase elevations were observed in 4 patients, of which 1 had concomitant total bilirubin elevation kzepqembbt (ctnitcpdth )
-
05 May 2015
Phase 2
285
(ervlidmmci) = yfjoxrphtv zxsvdwecpb (suyqhcbelt, 59 - 68)
Positive
01 Dec 2014
Placebo
(ervlidmmci) = tzamdivamo zxsvdwecpb (suyqhcbelt, 36 - 53)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free